Bingham Private Wealth LLC Invests $1.42 Million in Gilead Sciences, Inc. $GILD

Bingham Private Wealth LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,530 shares of the biopharmaceutical company’s stock, valued at approximately $1,415,000. Gilead Sciences accounts for 1.2% of Bingham Private Wealth LLC’s investment portfolio, making the stock its 22nd biggest holding.

Other hedge funds have also modified their holdings of the company. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $26,000. Financial Consulate Inc. grew its holdings in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the period. MTM Investment Management LLC grew its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. BOCHK Asset Management Ltd purchased a new position in shares of Gilead Sciences during the 4th quarter worth $31,000. Finally, Millstone Evans Group LLC grew its holdings in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $140.45 on Wednesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The firm has a market capitalization of $174.33 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.85 and a beta of 0.39. The business’s 50-day moving average is $144.99 and its two-hundred day moving average is $130.99. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a $0.82 dividend. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is 48.45%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This trade represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 299,280 shares of company stock worth $42,820,550 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Mizuho increased their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft raised their target price on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Leerink Partners raised their target price on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Finally, Wells Fargo & Company raised their target price on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $156.77.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: PEPFAR and The Global Fund agreed to further fund Gilead’s twice-yearly injectable HIV prevention drug lenacapavir, expanding access for up to an additional 1 million people (raising the total commitment to cover up to 3 million people through 2028) — a meaningful demand/volume win in low‑ and middle‑income markets that supports long‑term revenue visibility for GILD. PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
• Positive Sentiment: Recent analyst upgrades/target increases (Morgan Stanley raised its outlook; Citigroup bumped its price target to $165) bolster upside expectations and institutional sentiment toward GILD. Analyst model updates and higher targets can support buying interest. Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models
• Positive Sentiment: Gilead’s most recent quarterly results and FY‑2026 guidance remain supportive: an EPS beat and revenue above consensus, plus guidance that implies mid‑single‑digit growth — fundamentals that underpin valuation and dividend appeal. (Background company earnings and guidance referenced in recent coverage.) Here’s Why Gilead Sciences (GILD) Gained But Lagged the Market Today
• Neutral Sentiment: Market commentary notes GILD “gained but lagged the market,” reflecting that while company‑specific headlines are positive, broader market moves and sector dynamics are influencing relative performance. Useful for short‑term trading context. Here’s Why Gilead Sciences (GILD) Gained But Lagged the Market Today
• Neutral Sentiment: Coverage highlighting stocks with positive earnings momentum cites tools (Zacks Earnings ESP) that list Gilead among names to watch for potential beats — this is informational and may attract short‑term momentum traders but does not itself change fundamentals. Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
• Negative Sentiment: Cantor Fitzgerald cut its price target on GILD to $115, signaling some downside in analyst sentiment and providing ammunition for cautious investors; such cuts can pressure the stock if followed by more conservative estimates. Cantor Fitzgerald Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $115.00
• Negative Sentiment: Activist and advocacy pressure: AIDS Healthcare Foundation publicly protested Gilead over drug pricing, a reputational and regulatory risk that could fuel policy scrutiny or pricing concessions over time. Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.